Relmapirazin

From Wikipedia, the free encyclopedia
Relmapirazin
Clinical data
Trade namesLumitrace
Other namesMB-102
Legal status
Legal status
  • Investigational
Identifiers
  • (2R)-2-[[3,6-Diamino-5-[[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl]pyrazine-2-carbonyl]amino]-3-hydroxypropanoic acid
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC12H16N6O8
Molar mass372.294 g·mol−1
3D model (JSmol)
  • C([C@H](C(=O)O)NC(=O)C1=C(N=C(C(=N1)N)C(=O)N[C@H](CO)C(=O)O)N)O
  • InChI=1S/C12H16N6O8/c13-7-5(9(21)15-3(1-19)11(23)24)17-8(14)6(18-7)10(22)16-4(2-20)12(25)26/h3-4,19-20H,1-2H2,(H2,14,17)(H2,13,18)(H,15,21)(H,16,22)(H,23,24)(H,25,26)/t3-,4-/m1/s1
  • Key:XHNJXRDGTITISI-QWWZWVQMSA-N

Relmapirazin (MB-102) is an investigational fluorescent tracer that is exclusively excreted renally and is used to measure glomerular filtration rate of the kidneys.[1][2][3][4][5][6][7]

References[edit]

  1. ^ Dorshow, Richard B.; Shieh, Jeng-Jong; Debreczeny, Martin P. (17 March 2023). "Clinical results from a pilot multi-center study using a novel fluorescent tracer agent for renal function measurement". In Raghavachari, Ramesh; Berezin, Mikhail Y. (eds.). Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XIV. p. 19. doi:10.1117/12.2648541. ISBN 9781510659018. S2CID 257614179.
  2. ^ Orieux, Arthur; Samson, Chloé; Pieroni, Laurence; Drouin, Sarah; Dang Van, Simon; Migeon, Tiffany; Frere, Perrine; Brunet, Dorothée; Buob, David; Hadchouel, Juliette; Guihaire, Julien; Mercier, Olaf; Galichon, Pierre (5 June 2023). "Pulmonary hypertension without heart failure causes cardiorenal syndrome in a porcine model". Scientific Reports. 13 (1): 9130. Bibcode:2023NatSR..13.9130O. doi:10.1038/s41598-023-36124-1. ISSN 2045-2322. PMC 10241877. PMID 37277538.
  3. ^ Jang, Soo M.; Shieh, Jeng-Jong; Riley, Ivan R.; Dorshow, Richard B.; Mueller, Bruce A. (July 2023). "Adsorption and Clearance of the Novel Fluorescent Tracer Agent MB-102 During Continuous Renal Replacement Therapy: In Vitro Results". ASAIO Journal. 69 (7): 702–707. doi:10.1097/MAT.0000000000001943. ISSN 1058-2916. PMC 10298171. PMID 37071749.
  4. ^ Rosner, Mitchell H.; Sprangers, Ben; Sandhu, Geeta; Malyszko, Jolanta (November 2022). "Glomerular Filtration Rate Measurement and Chemotherapy Dosing". Seminars in Nephrology. 42 (6): 151340. doi:10.1016/j.semnephrol.2023.151340. PMID 37086497. S2CID 258266791.
  5. ^ McMahon, Blaithin A.; Rosner, Mitchell H. (February 2020). "GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer". Kidney360. 1 (2): 141–150. doi:10.34067/KID.0000952019. PMC 8809099. PMID 35372903.
  6. ^ Schneider, Antoine G.; Molitoris, Bruce A. (December 2020). "Real-time glomerular filtration rate: improving sensitivity, accuracy and prognostic value in acute kidney injury". Current Opinion in Critical Care. 26 (6): 549–555. doi:10.1097/MCC.0000000000000770. PMID 33002974. S2CID 222173308.
  7. ^ Dorshow, Richard B.; Johnson, James R.; Shieh, Jeng-Jong; Riley, I. Rochelle; Rogers, Thomas E.; Pino, Christopher J.; Johnston, Kimberly A.; Tang, Peter; Nolin, Thomas D.; Humes, H. David; Goldstein, Stuart L. (July 2023). "Transdermal Detection of MB-102 and Correlation to Meropenem Pharmacokinetics During Continuous Renal Replacement Therapy: In Vivo Results". ASAIO Journal. 69 (7): 708–715. doi:10.1097/MAT.0000000000001945. PMC 10298183. PMID 37097973.